A Phase 1 interventional study of AD-115A, AD-1151 in Gastric Ulcer, sponsored by Addpharma Inc.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Addpharma Inc. · Phase 1, Interventional, and Treatment
The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.
A randomized, open-label, single-dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of AD-115A and the administration of AD-1151 for healthy subjects in fasting state
112 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
This study's planned enrollment of 46 is below the median of 265 across 86 interventional studies indexed under Stomach Ulcer.
Browse Stomach Ulcer studies →Addpharma Inc. is the lead sponsor of 56 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Period 1 : Reference Drug(Rebanex Tab), Period 2 : Test Drug(Revaprazan sulfate) Single-dose oral administration of AD-115A (200 mg tablet) in Period 1, followed by single-dose oral administration of AD-1151 (200 mg tablet) in Period 2.
Drug: AD-115A, AD-1151
Period 1 : Test Drug(Revaprazan sulfate), Period 2 : Reference Drug(Rebanex Tab) Single-dose oral administration of AD-115A (200 mg tablet) in Period 1, followed by single-dose oral administration of AD-1151 (200 mg tablet) in Period 2.
Drug: AD-115A, AD-1151
Single-dose oral administration of AD-115A or AD-1151 (200 mg tablet), according to randomized sequence.
Maximum concentration of drug in plasma (Cmax)
Cmax of AD-115A
Time frame: pre-dose to 24 hours
Area under the plasma concentration-time curve during dosing interval (AUCt)
AUCt of AD-115A
Time frame: pre-dose to 24 hours
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Addpharma Inc.